AR058380A1 - Inhibidores del factor viia macrociclicos utiles como anticoagulantes - Google Patents

Inhibidores del factor viia macrociclicos utiles como anticoagulantes

Info

Publication number
AR058380A1
AR058380A1 ARP060105501A ARP060105501A AR058380A1 AR 058380 A1 AR058380 A1 AR 058380A1 AR P060105501 A ARP060105501 A AR P060105501A AR P060105501 A ARP060105501 A AR P060105501A AR 058380 A1 AR058380 A1 AR 058380A1
Authority
AR
Argentina
Prior art keywords
substituted
heterocycle
nrcrd
alkyl
orb
Prior art date
Application number
ARP060105501A
Other languages
English (en)
Inventor
Nicholas Wurtz
Peter W Glunz
Eldon Scott Priestley
Daniel L Cheney
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR058380A1 publication Critical patent/AR058380A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/02—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
    • C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/04—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque tiene la formula (1), o un estereoisomero, tautomero, sal farmacéuticamente aceptable, solvato, o forma de profármaco del mismo, en donde, el anillo A es fenilo o un isomero de piridilo definido al reemplazar uno de CR1, CR2, CR3, o CR4 en el anillo A de la formula (1) con N; el anillo B es fenilo o un isomero de piridilo definido al reemplazar uno de CR8, CR9, CR10, o CR11 en el anillo B de la formula (1) con N; para las definiciones de M y L, como se describen de izquierda a derecha, el átomo conectivamente esta en el orden (el anillo A)-L-M-(el anillo B); M es -CONH-, -SO2NH-, -NHCO-, o -NHSO2; cuando M es -CONH-, L se selecciona de -C(R12R13)C(R12R13)-, -XC(R12R13)-, -C(R12R13)Y-, - C(R12R13)C(R12R13)C(R12R13)-, -XC(R12R13)C(R12R13)-, -C(R12R13)XC(R12R13)-, -C(R12R13)C(R12R13)Y-, -XC(R12R13)Y-, -C(R12R13)C(R12R13)C(R12R13)C(R12R13)-, XC(R12R13)C(R12R13)C(R12R13)-, -C(R12R13)XC(R12R13)C(R12R13)-, -C(R12R13)C(R12R13)XC(R12R13)-, - C(R12R13)C(R12R13)C(R12R13)Y-, -XC(R12R13)C(R12R13)Y-, -XC(R12R13)XC(R12R13)-, y -C(R12R13)XC(R12R13)Y-; cuando M es -SO2NH-, L se selecciona de -C(R12R13)C(R12R13)-, -C(R12R13)C(R12R13)C(R12R13)-, -XC(R12R13)C(R12R13)-, - C(R12R13)C(R12R13)C(R12R13)C(R12R13)-, -XC(R12R13)C(R12R13)C(R12R13)-, -C(R12R13)XC(R12R13)C(R12R13)-, -C(R12R13)XC(R12R13)-, -C(R12R13)C(R12R13)Y-, -C(R12R13)C(R12R13)XC(R12R13)-, -C(R12R13)C(R12R13)C(R12R13)Y-, -XC(R12R13)C(R12R13)Y-, - XC(R12R13)XC(R12R13)-, -C(R12R13)XC(R12R13)Y-; cuando M es -NHCO-, L se selecciona de -C(R12R13)C(R12R13)-, -C(R12R13)C(R12R13)C(R12R13)-, -XC(R12R13)C(R12R13)-, -C(R12R13)C(R12R13)C(R12R13)-, -XC(R12R13)C(R12R13)C(R12R13)-, y - C(R12R13)XC(R12R13)C(R12R13)-; cuando M es -NHSO2-, L se selecciona de -C(R12R13)C(R12R13), -C(R12R13)C(R12R13)C(R12R13), -XC(R12R13)C(R12R13)-, -C(R12R13)C(R12R13)C(R12R13)C(R12R13)-, -XC(R12R13)C(R12R13)C(R12R13)-, y -C(R12R13)XC(R12R13)C(R12R13)- ; W es substituido con 0-2 R14 y se selecciona de un elemento del grupo de formulas (2); X es O, S(O)p, o NR16; Y es O o NR16a; Z es NH, O o S; R1 es H, F, CI, Br, I, alquilo C1-4 substituido con 0-1 OH, fluoroalquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alquiltio C1-4, o cicloalquilo C3-6; R2 es H, F, CI, Br, I, -(CH2)sORa, -(CH2)sSRb, -(CH2)sCF3, -(CH2)sOCF3, -(CH2)sOCHF2, -(CH2)sOCH2F, -(CH2)sCN, -(CH2)sNO2, -(CH2)sNRcRd, -(CH2)sC(O)Ra, -(CH2)sCO2Ra, -(CH2)sNRcC(O)Ra, - (CH2)sC(O)NRcRd, -(CH2)sNRcC(O)ORb, -(CH2)sOC(O)ORb, -(CH2)sNRcC(O)NRcRd, -(CH2)sOC(O)NRcRd, -(CH2)sSO2NRcRd, -(CH2)sNRcSO2NRcRd, -(CH2)sNRcSO2Rb, (CH2)sNRcSO2CF3, -(CH2)sSO2CF3, -(CH2)sS(O)2Rb, alquilo C1-6 substituido con 0-2 Re, fluoroalquilo C1- 4, alquenilo C2-4 substituido con 0-2 Re, alquinilo C2-4 substituido con 0-2 Re, -(CH2)s-carbociclo C3-6 substituido con 0-2 Rf, -(CH2)s-(heterociclo de 5 hasta 6 miembros), -(CH2)sNRc-(heterociclo de 5 hasta 6 miembros), o -(CH2)s-O-(heterociclo de 5 hasta 6 miembros); en donde el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0-2 Rg; R3 es H, F, CI, Br, I, -(CH2)sORa, -(CH2)sSRb, -(CH2)sCF3, -(CH2)sOCF3, -(CH2)sOCHF2, - (CH2)sOCH2F, -(CH2)sCN, -(CH2)sNO2, (CH2)sNRcRd, (CH2)sC(O)Ra, -(CH2)sCO2Ra, -(CH2)sNRcC(O)Ra, -(CH2)sC(O)NRcRd, -(CH2)sNRcC(O)ORb, -(CH2)sOC(O)ORb, -(CH2)sNRcC(O)NRcRd, (CH2)sOC(O)NRcRd, -(CH2)sSO2NRcRd, -(CH2)sNRcSO2NRcRd, -(CH2)sNRcSO2Rb, - (CH2)sNRcSO2CF3, -(CH2)sSO2CF3, -(CH2)sS(O)2Rb, -O(CH2)nCO2Ra, -(CH2)sSO2NHCORb, -(CH2)sCONHSO2Rb, alquilo C1-6 substituido con 0-2 Re, fluoroalquilo C1-4, alquenilo C2-4 substituido con 0-2 Re, alquinilo C2-4 substituido con 0-2 Re, -O(bencilo substituido con CO2Ra), -(CH2)stetrazolilo, -(CH2)scarbociclo C3-6 substituido con 0-2 Rf1, -(CH2)s-(heterociclo de 5 hasta 6 miembros), -(CH2)s-NRc-(heterociclo de 5 hasta 6 miembros), o -(CH2)s-O-(heterociclo de 5 hasta 6 miembros); en donde el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0-2 Rg1; alternativamente, R2 y R3 pueden combinarse para formar un carbociclo o heterociclo de 5 hasta 7 miembros que comprende: átomos de carbono y 0-2 heteroátomos seleccionados de N, NRc, O, y S(O)p; en donde el carbociclo y heterociclo están substituidos con 0-3 Rg1; R4 es H, F, CI, Br, I, o alquilo C1-4; R5 es H, -(CH2)qORa, -(CH2)qSRb, -(CH2)rCF3, -(CH2)qOCF3, - (CH2)qOCHF2, -(CH2)qOCH2F, -(CH2)qCN, -(CH2)qNO2, -(CH2)qNRcRd, -(CH2)sC(O)Ra, -(CH2)sCO2Ra, -(CH2)qNRcC(O)Ra, -(CH2)sC(O)NRcRd, -(CH2)qNRcC(O)ORb, -(CH2)qOC(O)ORb, -(CH2)qNRcC(O)NRcRd, -(CH2)qOC(O)NRcRd, -(CH2)qSO2NRcRd, -(CH2)qNRcSO2NRcRd, - (CH2)qNRcSO2Rb, -(CH2)qNRcSO2CF3, -(CH2)qSO2CF3, -(CH2)qS(O)2Rb, -(CH2)qSO2NHCORb, -(CH2)qCONHSO2Rb, -O(bencilo substituido con CO2Ra), -(CH2)stetrazolilo, alquilo C1-6 substituido con 0-2 Re, alquenilo C2-4 substituido con 0-2 Re, alquinilo C2-4 substituido con 0-2 Re, -(CH2)s-carbociclo C3-6 substituido con 0-2 Rf1, o heterociclo-(CH2)s- de 5 hasta 6 miembros; en donde el heterociclo comprende átomos de carbono y '1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0- 2 Rg1; R6 es H, -(CH2)rORa, -(CH2)rSRb, -(CH2)sCF3, -(CH2)rOCF3, -(CH2)rOCHF2, -(CH2)rOCH2F, -(CH2)sCN, -(CH2)sNO2, -(CH2)rNRcRd, -(CH2)sC(O)Ra, -(CH2)sCO2Ra, -(CH2)rNRcC(O)Ra, -(CH2)sC(O)NRcRd, -(CH2)rNRcC(O)ORb, -(CH2)rOC(O)ORb, - (CH2)rNRcC(O)NRcRd, -(CH2)rOC(O)NRcRd, -(CH2)rSO2NRcRd, -(CH2)rNRcSO2NRcRd, - (CH2)rNRcSO2Rb, -(CH2)rNRcSO2CF3, -(CH2)rSO2CF3, -(CH2)rS(O)2Rb, -(CH2)rSO2NHCORb, -(CH2)sCONHSO2Rb, alquilo C1-6 substituido con 0-2 Re, alquenilo C2-4 substituido con 0- 2 Re, alquinilo C2-4 substituido con 0-2 Re, -(CH2)s-carbociclo C3-6 substituido con 0-2 Rf1 o heterociclo-(CH2)s- de 5 hasta 6 miembros; en donde el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0-2 Rg1; alternativamente, R5 y R6 pueden unirse para formar una cadena alquileno de 2 hasta 5 miembros, la cual puede ser substituida con 0-1 Rf1; R7 es H o alquilo C1-6; alternativamente, R6 y R7 pueden unirse para formar un carbociclo o heterociclo de 3-7 miembros; en donde el carbociclo puede ser substituido con 0-2 Rf1; y el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0-2 Rg1; R8 es H, F, CI, Br, CN, CH2F, CHF2, -(CH2)sCF3, -(CH2)sOCF3, -(CH2)sSCF3, -(CH2)sOCHF2, -(CH2)sOCH2F, -(CH2)sCN, -(CH2)sNO2, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, -(CH2)n-ORa, -(CH2)nSRb, -(CH2)nNRcRd, -(CH2)sC(O)Ra, -(CH2)sCO2Ra, -(CH2)sNRcC(O)Ra, - (CH2)sCONRcRd, -(CH2)sSO2Rb, -(CH2)sSO2NRcRd, -(CH2)sNRcC(O)ORb, -(CH2)sOC(O)ORb, -(CH2)sNRcC(O)NRcRd, -(CH2)sOC(O)NRcRd, -(CH2)sNRcSO2NRcRd, -(CH2)sNRcSO2Rb, -(CH2)sNRcSO2CF3, -(CH2)sSO2CF3, -O(CH2)nCO2Ra, -(CH2)sSO2NHCORb, -(CH2)sCONHSO2Rb, - O(bencilo substituido con CO2Ra), -(CH2)stetrazolilo, alquilo C1-6 substituido con 0-2 Re, fluoroalquilo C1-4, alquenilo C2-4 substituido con 0-2 Re, alquinilo C2-4 substituido con 0-2 Re, -(CH2)s-carbociclo C3-6 substituido con 0-2 Rf1, o heterociclo-(CH2)s- de 5 hasta 10 miembros que comprende: átomos de carbono y 1-4 heteroátomos seleccionados de N, NRc, O y S(O)p, en donde el fenilo y heterociclo están substituidos con 0-3 Rg1; R9, R10, y R11 son independientemente cada que se presentan H, E, CI, Br, I, alquilo C1-4, o alcoxi C1-4; R12 y R13 son independientemente cada que se presentan F, CI, ORa. SRb, CF3, OCF3, OCHF2, OCH2F, CN, NO2, .NRcRd, -C(O)Ra, -CO2Ra, NRcC(O)Ra, C(O)NRcRd, NRcC(O)ORb, -NRcC(O)NRcRd, OC(O)NRcRd, - OC(O)ORa, -SO2NRcRd, -NRcSO2NRcRd, -NRcSO2Rb, -NRcSO2CF3, -SO2CF3, -S(O)2Rb, alquilo C1-6 substituido con 0-2 Re, alquenilo C2-4 substituido con 0-2 Re, alquinilo C2-4 substituido con 0-2 Re, -(CH2)s-carbociclo C3-6 substituido con 0-2 Rf1, -(CH2)s- (heterociclo de 5 hasta 6 miembros), -NR-(heterociclo de 5 hasta 6 miembros)1 o -O-(heterociclo de 5 hasta 6 miembros); en donde el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0- 2 Rg1; alternativamente, cualquiera de dos R12 o R13 se enlazan ya sea al mismo carbono o a dos carbonos adyacentes pueden combinarse para formar un carbociclo o heterociclo de 3 hasta 7 miembros que comprende: átomos de carbono y 0-3 heteroátomos seleccionados de N, NRc, O, y S(O)p, en donde el carbociclo o heterociclo es substituido con 0-3 Rg; opcionalmente, dos R12 o R13 en átomos de carbono adyacentes en L pueden ser reemplazados con un enlace doble o triple entre los dos átomos de carbono; R14 es independientemente cada que se presenta CN, F, CI, Br, I, OH, N(R17R17), alquilo C1-3, o alcoxi C1-3; R15 es independientemente cada que se presenta H, -C(=NH)NH2, N(R17R17), -C(R17R17)N(R17R17), -CON(R17R17), CN, F, CI, Br, I, OH, alquilo C1-3, o alcoxi C1-3; R16 es independientemente cada que se presenta H, alquilo C1-4, cicloalquilo C3-6, fenilo, bencilo, -C(O)Ra, -C(O)NRcRd, -C(O)ORb, -SO2NRcRd, -SO2CF3, -S(O)2Rb, o -(CH2)s(heterociclo de 5 hasta 6 miembros); en donde el alquilo o cicloalquilo son opcionalmente substituidos con 0-2 Re, el fenilo y bencilo son opcionalmente substituidos con 0-2 Rf, y el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0-2 Rg; R16a es independientemente cada que se presenta H, alquilo C1-6, cicloalquilo C3-6, fenilo, bencilo, C(O)Ra, C(O)NRcRd, C(O)ORb, SO2NRcRd, -SO2CF3, S(O)2Rb, o heterociclo de 5 hasta 6 miembros; en donde el alquilo o cicloalquilo son opcionalmente substituidos con 0-2 Re, el fenilo y bencilo son opcionalmente substituidos con 0-2 Rf, y el heterociclo comprende átomos de carbono y 1-3 heteroátomos seleccionados de N, NRc, O, y S(O)p y es substituido con 0-2 Rg; R17 es independientemente cada que se presenta H o Me; Ra es independientemente cada que se presenta H, alquilo C1-4, cicloalquilo C3-6, fenilo, o bencilo; en donde el alquilo y cicloalquilo son opcion
ARP060105501A 2005-12-23 2006-12-13 Inhibidores del factor viia macrociclicos utiles como anticoagulantes AR058380A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75378605P 2005-12-23 2005-12-23
US86547506P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
AR058380A1 true AR058380A1 (es) 2008-01-30

Family

ID=37897422

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105501A AR058380A1 (es) 2005-12-23 2006-12-13 Inhibidores del factor viia macrociclicos utiles como anticoagulantes

Country Status (16)

Country Link
US (2) US7592331B2 (es)
EP (1) EP1971582B1 (es)
JP (1) JP5139999B2 (es)
KR (1) KR20080087848A (es)
AR (1) AR058380A1 (es)
AU (1) AU2006330495A1 (es)
BR (1) BRPI0620254A2 (es)
CA (1) CA2634794A1 (es)
EA (1) EA200801592A1 (es)
ES (1) ES2395052T3 (es)
IL (1) IL192105A0 (es)
NO (1) NO20082629L (es)
NZ (1) NZ568715A (es)
PE (1) PE20071132A1 (es)
TW (1) TW200745062A (es)
WO (1) WO2007076431A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
EP2099783A1 (en) * 2006-12-20 2009-09-16 Brystol-Myers Squibb Company Bicyclic lactam factor viia inhibitors useful as anticoagulants
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TWI586651B (zh) 2011-10-14 2017-06-11 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之經取代四氫異喹啉化合物
EP2858977A1 (en) 2012-06-08 2015-04-15 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059203A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9738655B2 (en) 2013-03-25 2017-08-22 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors
EP3008052A1 (en) * 2013-06-13 2016-04-20 Bristol-Myers Squibb Company Macrocyclic factor viia inhibitors
NO2760821T3 (es) 2014-01-31 2018-03-10
CN110845498B (zh) 2014-01-31 2023-02-17 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
WO2016036893A1 (en) 2014-09-04 2016-03-10 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6742348B2 (ja) * 2015-06-19 2020-08-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としてのジアミド大員環
CN115404020B (zh) * 2022-10-14 2023-06-30 深圳市高仁电子新材料有限公司 一种用于全贴合和柔性折叠屏的三层结构的丙烯酸类光学胶膜及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5866542A (en) * 1994-10-18 1999-02-02 Corvas International, Inc. Nematode-extracted anticoagulant protein
WO1999013063A1 (en) * 1997-09-09 1999-03-18 Nycomed Imaging As Factor vii fragments and analogs thereof and their use in the treatment of blood clottng disorders
EP1332131A2 (en) * 2000-11-07 2003-08-06 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
AU2002322802A1 (en) 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
US7122559B2 (en) * 2003-02-11 2006-10-17 Bristol-Myers Squibb Company Phenylglycine derivatives useful as serine protease inhibitors
JP2006517589A (ja) * 2003-02-11 2006-07-27 ブリストル−マイヤーズ　スクイブ　カンパニー セリンプロテアーゼ・インヒビターとして有用なベンゼンアセトアミド化合物
DE602006016566D1 (de) * 2005-01-10 2010-10-14 Bristol Myers Squibb Co Als antikoagulanzien verwendbare phenylglycinamid-derivate
US7456195B2 (en) * 2005-06-24 2008-11-25 Bristol-Myers Squibb Company Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants

Also Published As

Publication number Publication date
WO2007076431A1 (en) 2007-07-05
AU2006330495A1 (en) 2007-07-05
US20090281139A1 (en) 2009-11-12
NO20082629L (no) 2008-09-05
US7592331B2 (en) 2009-09-22
BRPI0620254A2 (pt) 2011-11-08
JP2009521505A (ja) 2009-06-04
IL192105A0 (en) 2008-12-29
EP1971582B1 (en) 2012-10-10
PE20071132A1 (es) 2007-12-14
JP5139999B2 (ja) 2013-02-06
EA200801592A1 (ru) 2008-12-30
US20070208054A1 (en) 2007-09-06
KR20080087848A (ko) 2008-10-01
CA2634794A1 (en) 2007-07-05
EP1971582A1 (en) 2008-09-24
TW200745062A (en) 2007-12-16
ES2395052T3 (es) 2013-02-07
NZ568715A (en) 2011-01-28

Similar Documents

Publication Publication Date Title
AR058380A1 (es) Inhibidores del factor viia macrociclicos utiles como anticoagulantes
AR064471A1 (es) Macrociclos inhibidores selectivos del factor de coagulacion viia, composiciones farmaceuticas que los comprenden y uso de los mismos como agentes anticoagulantes.
CL2004000076A1 (es) Compuestos derivados de indol, inhibidores de polimerasa, sales; composicion farmaceutica que los comprende; procedimiento de preparacion de dichos compuestos; compuestos intermediarios; y uso del compuesto para tratar una infeccion causada por el vi
DOP2019000218A (es) Inhibidores de las proteasas de serina del vhc derivados de prolinas macrocíclicas
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR101106A1 (es) Inhibidores de tirosina quinasa de bruton
AR084393A1 (es) Metodos para tratar el virus de la hepatitis c, composicion, uso, combinacion, kit y uno o mas compuestos anti vhc
AR076579A1 (es) Espironucleosidos uracilicos oxetanicos, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del virus de la hepatitis c (vhc).
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
AR034282A1 (es) Derivados de difenilazetidinona, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para la preparacion de medicamentos
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
CL2008003384A1 (es) Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
AR056986A1 (es) Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas
AR068479A1 (es) (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica
AR082015A1 (es) Derivados de metoxifenilo heterociclicamente sustituidos con un grupo oxo, procedimientos para su preparacion y uso de los mismos como medicamentos
AR043210A1 (es) Compuestos de triazol utiles en terapia
AR043929A1 (es) Fases cristalinas de un inhibidor del hcv
EA201100928A1 (ru) Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов
AR070345A1 (es) (dihidro ) pirrolo (2,1-a) isoquinolinas
ECSP055745A (es) Derivados de 1-(4-bencil-piperazin-1-il)-3-fenil-propenona

Legal Events

Date Code Title Description
FB Suspension of granting procedure